2,850
Participants
Start Date
September 8, 2025
Primary Completion Date
May 29, 2026
Study Completion Date
May 29, 2026
OVX836 480µg
One single administration intramuscularly at Day 1.
Saline Solution
One single administration intramuscularly at Day 1.
Lead Sponsor
Site BE-01, Ghent, Belgium
UNKNOWN
Site BE-02, Antwerp, Belgium
UNKNOWN
Site BE-03, Antwerp, Belgium
UNKNOWN
Site BE-04, Mechelen, Belgium
UNKNOWN
Site FR-05, Lyon, France
UNKNOWN
Site FR-06, Rennes, France
UNKNOWN
Site FR-07, Paris, France
UNKNOWN
Site FI-08, Helsinki, Finland
UNKNOWN
Site FI-09, Tampere, Finland
UNKNOWN
Site FI-10, Turku, Finland
UNKNOWN
Site FI-11, Oulu, Finland
UNKNOWN
Site FI-12, Espoo, Finland
UNKNOWN
Site FI-13, Järvenpää, Finland
UNKNOWN
Site FI-14, Kokkola, Finland
UNKNOWN
Site FI-15, Seinäjoki, Finland
UNKNOWN
Site DE-16, Munich, Germany
UNKNOWN
Osivax
INDUSTRY